Update - ATAGI recommendations on the use of a booster dose of COVID-19 vaccine

The Australian Technical Advisory Group on Immunisation (ATAGI) has released version 3 of its recommendations on the use of additional (booster) doses of COVID-19 vaccine.

Changes include:

Nuvaxovid (Novavax) can be used as a booster in an individual aged 18 years and above if no other COVID-19 vaccine is considered suitable for that individual.
Recommendations concerning the use of AstraZeneca COVID-19 vaccine as a booster dose have been updated. AstraZeneca is no longer recommended for use as the booster dose for people who received a primary vaccination course of the AstraZeneca COVID-19 vaccine, although it can still be used for this purpose if these individuals decline receiving an mRNA vaccine as a booster dose. AstraZeneca is now only recommended when there are medical contraindications to the mRNA vaccines.
Comirnaty (Pfizer) can be used as a booster in individuals aged 16 years and above.
Updated evidence of vaccine effectiveness of booster doses against the Omicron variant has been included.

You can read the full document here.

You are currently on:

Update - ATAGI recommendations on the use of a booster dose of COVID-19 vaccine

Healthy rural, remote and First Nations communities through excellence, social accountability and innovation.